Table 2 Liquid biopsy analytes and potential utility as prognostic biomarkers
From: Potential clinical utility of liquid biopsies in ovarian cancer
Analyte | Author, Year | Tumour Subtype and Staging | Number of patients | Laboratory Technique | Prognostic Significance | Ref |
|---|---|---|---|---|---|---|
CTCs | Zhang et al., 2018 | Stage I-IV EOC | 109 | Immunomagnetic bead screening, RT-PCR | OS (p = 0.041) | [181] |
Poveda et al., 2011 | Stage I-IV EOC | 216 | CellSearch system and reagents | OS (p = 0.0017) PFS (p = 0.00024) | [183] | |
Judson et al., 2003 | Stage I-IV EOC | 64 | Immunocytochemical assay | NS | [196] | |
Aktas et al., 2011 | Stage I-IV EOC | 122 | AdnaTest BreastCancer, RT-PCR | OS (p = 0.0054) | [199] | |
Chebouti et al., 2017 | Stage I-IV EOC | 65 | AdnaTest Ovarian Cancer, RT-PCR | OS (p = 0.0008) PFS (p = 0.0293) | [200] | |
Kuhlamann et al., 2014 | Stage I-IV EOC | 143 | Multiplex RT-PCR, immunomagnetic CTC enrichment | OS (p = 0.026) PFS (p = 0.009) | [16] | |
Obermayr et al., 2013 | Stage I-IV EOC | 216 | RT-qPCR, microarray analysis | OS (p = 0.001) PFS (p = 0.001) | [21] | |
Obermayr et al., 2017 | Stage I-IV EOC | 266 | Density gradient centrifugation, immunostaining, FISH | OS (p = 0.007) PFS (p = 0.008) | [201] | |
ctDNA | Giannopoulou et al., 2017 | Stage I-IV EOC | 59 | Methylation-sensitive high-resolution melting analysis (MS-HRMA) assay | OS (p = 0.023) | [153] |
Pereira et al., 2015 | Stage I-IV EOC | 10 | Droplet digital PCR | OS (p = 0.0011) PFS (p = 0.0194) | [163] | |
Parkinson et al., 2016 | Stage I-IV EOC | 40 | Microfluidic digital PCR | TTP (p = 0.008) | [164] | |
Swisher et al., 2005 | Stage I-IV EOC | 137 | DNA sequencing, PCR | OS (p = 0.02) | [58] | |
Giannopoulou et al., 2018 | Stage I-IV EOC | 53 | Methylation-specific PCR | OS (p = 0.027) PFS (p = 0.041) | [170] | |
No et al., 2012 | Stage I-IV EOC | 36 | Copy number assay, qPCR | OS (HR = 33.6, 95% CI = 1.8–634.8) DFS (HR = 18.2, 95% CI = 2.0–170.0) | [178] | |
Kuhlmann et al., 2012 | Stage I-IV EOC | 63 | PCR-based fluorescence microsatellite analysis | OS (p = 0.030) | [179] | |
Pearl et al., 2014 | Stage I-IV EOC | 129 | CAM-based identification platform | CTCs were better correlated with worse OS and PFS compared to CA125 | [184] | |
Pearl et al., 2015 | Stage I-IV EOC | 123 | iCTC flow cytometry assay | CTCs more sensitive to progressive disease and relapse compared to CA125 | [185] | |
Minato et al., 2021 | Stage I-IV EOC | 11 | Droplet digital PCR | Earlier recurrence detection compared to CA125 | [195] | |
Kim et al., 2019 | Stage II-IV EOC | 61 | Droplet digital PCR | TTP (p = 0.038) | [189] | |
Paracchini et al., 2020 | Stage III-IV EOC | 46 | Shallow whole-genome sequencing | PFS (p = 0.011) | [204] | |
cfRNA | Zuberi et al., 2015 | Stage I-IV EOC | 70 | Trizol method | Disease progression (p = 0.001) | [189] |
Halvorsen et al., 2017 | Stage I-IV EOC | 207 | TaqMan Low Density Arrays, RT-qPCR | OS (p = 0.012) PFS (p = 0.006) | [203] | |
Zhang et al., 2019 | Stage I-IV EOC | 40 | liquid chromatography tandem mass spectrometry | OS (p = 0.0012) PFS (p = 0.00038) | [186] | |
Exosomes | Schwich et al., 2019 | Stage I-IV EOC | 78 | Nanoparticle tracking analysis, ELISA | PFS (p = 0.029) | [187] |